Plant Comparison
Bay-leaf willowherb vs Goldenrod
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Bay-leaf willowherb and Goldenrod: they share 6 indicated uses (arthritis / joint pain, cancer (anticancer research), inflammation (general), …); 3 pharmacological actions in common.
Evidence face-off — shared uses
| Condition | Bay-leaf willowherb | Goldenrod | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 1/10 | 1/10 | Comparable evidence |
| Cancer (anticancer research) | 2/10 | 2/10 | Comparable evidence |
| Inflammation (general) | 1/10 | 2/10 | Comparable evidence |
| Skin irritation | 1/10 | 1/10 | Comparable evidence |
| Urinary support | 5/10 | 7/10 | Stronger for Goldenrod |
| Urinary tract infection (UTI) | 5/10 | 2/10 | Stronger for Bay-leaf willowherb |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Characteristic Epilobium polyphenols underlying the anti-inflammatory and prostate activity; a genus review identifies oenothein B as the dominant constituent and likely driver of the antimicrobial, anti-inflammatory, anti-proliferative and antioxidant effects.
Antioxidant constituents.
Sterols associated with benign prostatic hyperplasia support.
Pharmacological Actions
Traditional & Indicated Uses
inferred from anti-inflammatory action
inferred from anticancer action
inferred from antimicrobial action
inferred from anti-inflammatory action
Supports lower urinary tract symptoms of benign prostatic hyperplasia (prostate support) - a genus Epilobium review notes traditional BPH use attributed mainly to oenothein B, though clinical evidence is not yet conclusive
inferred from anti-inflammatory action
Antibacterial, including against Escherichia coli (urinary support); Supports lower urinary tract symptoms of benign prostatic hyperplasia (prostate support) - a genus Epilobium review notes traditional BPH use attributed mainly to oenothein B, though clinical evidence is not yet conclusive
Supports lower urinary tract symptoms of benign prostatic hyperplasia (prostate support) - a genus Epilobium review notes traditional BPH use attributed mainly to oenothein B, though clinical evidence is not yet conclusive
inferred from anti-inflammatory action
inferred from anticancer action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from diuretic action
Safety, Cautions & Contraindications
Lower urinary tract / prostate symptoms must be medically assessed first to exclude prostate cancer; willowherb is a supportive measure, not a substitute for diagnosis and treatment.
Well tolerated over three months in clinical use; longer-term safety data are limited.
Generally well tolerated. Not recommended in cases of fluid retention due to impaired cardiac or renal function. Ensure adequate fluid intake when using as a diuretic. May cause allergic reactions in individuals sensitive to Asteraceae plants. Avoid use during pregnancy and breastfeeding due to limited safety data.
Duke (2002) provides clinical evidence (score 2) for goldenrod's anti-inflammatory activity, consistent with Commission E approval. It is also classified as an aquaretic (increases urine output without electrolyte loss) and antispasmodic, used for urinary tract irrigation therapy. Dose: 6–12 g dried herb daily as tea for urinary complaints. Duke cautions against use in cases of edema from renal or cardiac insufficiency, and notes that the herb may cause allergic reactions in individuals sensitive to Asteraceae plants (Duke, 2002).
External Ids
Botanical Description
Slender, softly hairy perennial herb with narrow, lance-shaped leaves and small, four-petalled, pale pink to lilac flowers with a notched tip, borne singly in the upper leaf axils. After flowering, long, narrow seed pods split to release cottony-tufted seeds, typical of the willowherb genus.[13]
Perennial herb (Asteraceae), 20-100 cm tall, with erect, often reddish, downy or smooth stems. Leaves are alternate, lance-shaped and toothed. Numerous small, bright yellow, daisy-like flower heads are clustered into branched, plume-like terminal sprays, followed by small ribbed achenes with a tuft of hairs (pappus).[1]
Habitat
Grows in damp meadows, ditches, streamsides and waste ground on moist soils; native to Europe and temperate Asia.[13]
Harvesting
The flowering aerial parts are cut in summer while in flower, and dried in a warm, shaded, airy place.[13]
The flowering aerial parts are cut during flowering (late summer) and dried.[11]
Traditional Uses
Small-flowered willowherb, along with related Epilobium species, has a Central European folk tradition as a supportive remedy for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH) and prostatitis, and as an antimicrobial and anti-inflammatory herb for minor infections; the traditional prostate-support use is attributed mainly to its oenothein B content, though robust clinical evidence remains limited.[13]
Goldenrod has a long European folk-medicine tradition as a mild 'aquaretic' diuretic and anti-inflammatory remedy for the urinary tract, used traditionally for urinary-tract irrigation therapy alongside adequate fluid intake, and topically as a wound herb (one common name is 'woundwort'). Modern phytochemical work confirms saponin- and flavonoid-driven anti-inflammatory, antioxidant and diuretic activity.[1, 11]
Preparations
Dosage
The EU herbal monograph gives 1.5-2.0 g of the comminuted herb in 250 mL of boiling water as an infusion, twice daily, in adults and elderly; long-term use is possible. Lower urinary tract or prostate symptoms should always be medically assessed first, and the monograph directs that a doctor be consulted if fever, spasms, blood in the urine, painful urination or urinary retention occur. Educational reference only, not a prescription.
References
Lookalikes Review
Dangerous Lookalikes
Not documented
References & Sources
- Vitalone, A. and Allkanjari, O (2018) 'Epilobium spp: Pharmacology and Phytochemistry', Phytotherapy Research, 32(7), pp. 1229-1240. doi:10.1002/ptr.6072 Traditional / reference
https://doi.org/10.1002/ptr.6072 - Cicero, A.F.G., Allkanjari, O., Busetto, G.M., Cai, T. et al (2019) 'Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer', Archivio Italiano di Urologia e Andrologia, 91(3), pp. 139-152. doi:10.4081/aiua.2019.3.139 Traditional / reference
https://doi.org/10.4081/aiua.2019.3.139 - Vlase, A.M., Toiu, A., Gligor, O., Muntean, D. et al (2024) 'Investigation of Epilobium hirsutum L. Optimized Extract's Anti-Inflammatory and Antitumor Potential', Plants (Basel), 13(2), pp. 198. doi:10.3390/plants13020198 Preclinical
https://doi.org/10.3390/plants13020198 - Granica, S., Piwowarski, J.P., Czerwinska, M.E. and Kiss, A.K (2014) 'Phytochemistry, pharmacology and traditional uses of different Epilobium species (Onagraceae): a review', Journal of Ethnopharmacology, pp. 316--346. doi:10.1016/j.jep.2014.08.036 Traditional / reference
https://doi.org/10.1016/j.jep.2014.08.036 - Ramstead, A.G., Schepetkin, I.A., Quinn, M.T. and Jutila, M.A (2012) 'Oenothein B, a cyclic dimeric ellagitannin isolated from Epilobium angustifolium, enhances IFN-gamma production by lymphocytes', PLoS One, 7(11), pp. e50546. doi:10.1371/journal.pone.0050546 Preclinical
https://doi.org/10.1371/journal.pone.0050546 - Kiss, A.K., Bazylko, A., Filipek, A., Granica, S., Jaszewska, E., Kiarszys, U., Kosmider, A. and Piwowarski, J (2011) 'Oenothein B's contribution to the anti-inflammatory and antioxidant activity of Epilobium sp', Phytomedicine, 18(7), pp. 557-560. doi:10.1016/j.phymed.2010.10.016 Preclinical
https://doi.org/10.1016/j.phymed.2010.10.016 - Schepetkin, I.A., Kirpotina, L.N., Jakiw, L., Khlebnikov, A.I., Blaskovich, C.L., Jutila, M.A. and Quinn, M.T (2009) 'Immunomodulatory activity of oenothein B isolated from Epilobium angustifolium', Journal of Immunology, 183(10), pp. 6754-6766. doi:10.4049/jimmunol.0901827 Preclinical
https://doi.org/10.4049/jimmunol.0901827 - Ducrey, B., Marston, A., Gohring, S., Hartmann, R.W. and Hostettmann, K (1997) 'Inhibition of 5-alpha-reductase and aromatase by the ellagitannins oenothein A and oenothein B from Epilobium species', Planta Medica, 63(2), pp. 111-114. doi:10.1055/s-2006-957624 Preclinical
https://doi.org/10.1055/s-2006-957624 - Schepetkin, I.A., Ramstead, A.G., Kirpotina, L.N., Voyich, J.M., Jutila, M.A. and Quinn, M.T (2016) 'Therapeutic potential of polyphenols from Epilobium angustifolium (fireweed)', Phytotherapy Research, 30(8), pp. 1287-1297. doi:10.1002/ptr.5648 Meta-analysis / review
https://doi.org/10.1002/ptr.5648 - Merighi, S., Travagli, A., Tedeschi, P., Marchetti, N. and Gessi, S (2021) 'Antioxidant and anti-inflammatory effects of Epilobium parviflorum, Melilotus officinalis and Cardiospermum halicacabum plant extracts in macrophage and microglial cells', Cells, 10(10), pp. 2691. doi:10.3390/cells10102691 Preclinical
https://doi.org/10.3390/cells10102691 - Hevesi Toth, B., Blazics, B. and Kery, A (2009) 'Polyphenol composition and antioxidant capacity of Epilobium species', Journal of Pharmaceutical and Biomedical Analysis, 49(1), pp. 26-31. doi:10.1016/j.jpba.2008.09.047 Preclinical
https://doi.org/10.1016/j.jpba.2008.09.047 - Vitalone, A., McColl, J., Thome, D., Costa, L.G. and Tita, B (2003) 'Characterization of the effect of Epilobium extracts on human cell proliferation', Pharmacology, 69(2), pp. 79-87. doi:10.1159/000072360 Preclinical
https://doi.org/10.1159/000072360 - Steenkamp, V., Gouws, M.C., Gulumian, M., Elgorashi, E.E. and van Staden, J (2005) 'Studies on antibacterial, anti-inflammatory and antioxidant activity of herbal remedies used in the treatment of benign prostatic hyperplasia and prostatitis', Journal of Ethnopharmacology, pp. 2005. doi:10.1016/j.jep.2005.07.007 Traditional / reference
https://doi.org/10.1016/j.jep.2005.07.007 - European Medicines Agency (HMPC) (2015) 'European Union herbal monograph on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba'. Available at: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-epilobium-angustifolium-l-andor-epilobium-parviflorum-schreb-herba_en.pdf Traditional / reference
https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-epilobium-angustifolium-l-andor-epilobium-parviflorum-schreb-herba_en.pdf - Coulson, S., Rao, A., Beck, S.L., Steels, E., Gramotnev, H. and Vitetta, L (2013) 'A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation (containing Epilobium parviflorum) for the management of symptoms of benign prostatic hypertrophy', Complementary Therapies in Medicine. doi:10.1016/j.ctim.2013.01.007 Randomized trial
https://doi.org/10.1016/j.ctim.2013.01.007
- Fursenco, C., Calalb, T., Uncu, L., Dinu, M. and others (2020) 'Solidago virgaurea L.: A Review of Its Ethnomedicinal Uses, Phytochemistry, and Pharmacological Activities', Biomolecules, 10(12), pp. 1619. doi:10.3390/biom10121619 Meta-analysis / review
https://doi.org/10.3390/biom10121619 - Abdel Motaal, A., Ezzat, S.M., Tadros, M.G. and El-Askary, H.I (2016) 'In vivo anti-inflammatory activity of caffeoylquinic acid derivatives from Solidago virgaurea in rats', Pharmaceutical Biology, 54(12), pp. 2864-2870. doi:10.1080/13880209.2016.1190381 Preclinical
https://doi.org/10.1080/13880209.2016.1190381 - Précheur, I., Rolland, Y., Hasseine, L., Orange, F. and others (2020) 'Solidago virgaurea L. Plant Extract Targeted Against Candida albicans to Reduce Oral Microbial Biomass: A Double Blind Randomized Trial on Healthy Adults', Antibiotics, 9(4), pp. 137. doi:10.3390/antibiotics9040137 Randomized trial
https://doi.org/10.3390/antibiotics9040137 - Wojnicz, D., Tichaczek-Goska, D., Glensk, M. and Hendrich, A.B (2021) 'Is It Worth Combining Solidago virgaurea Extract and Antibiotics against Uropathogenic Escherichia coli Rods? An In Vitro Model Study', Pharmaceutics, 13(4), pp. 573. doi:10.3390/pharmaceutics13040573 Preclinical
https://doi.org/10.3390/pharmaceutics13040573 - El-Tantawy, W.H (2013) 'Biochemical effects of Solidago virgaurea extract on experimental cardiotoxicity', Journal of Physiology and Biochemistry, 70(1), pp. 33-42. doi:10.1007/s13105-013-0277-0 Preclinical
https://doi.org/10.1007/s13105-013-0277-0 - Gross, S.C., Goodarzi, G., Watabe, M., Bandyopadhyay, S. and others (2002) 'Antineoplastic activity of Solidago virgaurea on prostatic tumor cells in an SCID mouse model', Nutrition and Cancer, 43(1), pp. 76-81. doi:10.1207/S15327914NC431_9 Preclinical
https://doi.org/10.1207/S15327914NC431_9 - Starks, C.M., Williams, R.B., Goering, M.G., O'Neil-Johnson, M. and others (2010) 'Antibacterial clerodane diterpenes from Goldenrod (Solidago virgaurea)', Phytochemistry, 71(1), pp. 104-109. doi:10.1016/j.phytochem.2009.09.032 Preclinical
https://doi.org/10.1016/j.phytochem.2009.09.032 - Malicanin, M., Karabegovic, I., Dordevic, N., Mancic, S. and others (2024) 'Influence of the Extraction Method on the Biological Potential of Solidago virgaurea L. Essential Oil and Hydrolates', Plants, 13(16), pp. 2187. doi:10.3390/plants13162187 Preclinical
https://doi.org/10.3390/plants13162187 - Zehra, S.A., Bhattarai, P., Zhang, J., Liu, Y. and others (2022) 'Phytochemical Analysis and Evaluation of the Antidiabetic Activity of Solidago virgaurea Extracts', Current Bioactive Compounds, 19(4), pp. e150622206146. doi:10.2174/1573407218666220615143502 Preclinical
https://doi.org/10.2174/1573407218666220615143502 - Jang, Y.S., Wang, Z., Lee, J.M., Lee, J.Y. and others (2016) 'Screening of Korean Natural Products for Anti-Adipogenesis Properties and Isolation of Kaempferol-3-O-rutinoside as a Potent Anti-Adipogenetic Compound from Solidago virgaurea', Molecules, 21(2), pp. 226. doi:10.3390/molecules21020226 Preclinical
https://doi.org/10.3390/molecules21020226 - European Medicines Agency (2008) 'Community herbal monograph on Solidago virgaurea L., herba'. Traditional / reference
https://scholar.google.com/scholar?q=Community%20herbal%20monograph%20on%20Solidago%20virgaurea%20L.%2C%20herba - Bader, G., Binder, K., Hiller, K. and Zwintscher, U (1990) 'The saponins from Solidago virgaurea L', 45(8), pp. 618--622. Traditional / reference
https://scholar.google.com/scholar?q=The%20saponins%20from%20Solidago%20virgaurea%20L - Royal Botanic Gardens, Kew (n.d.). Available at: https://powo.science.kew.org Traditional / reference
https://powo.science.kew.org - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Grow Forage Cook Ferment 'Foraging Goldenrod (Solidago): Identification and Uses'. Available at: https://www.growforagecookferment.com/foraging-goldenrod/ Traditional / reference
https://www.growforagecookferment.com/foraging-goldenrod/ - Washington State Noxious Weed Control Board 'Tansy Ragwort (Senecio jacobaea)'. Available at: https://www.nwcb.wa.gov/weeds/tansy-ragwort Traditional / reference
https://www.nwcb.wa.gov/weeds/tansy-ragwort - Schneider, J. and Tsegaye, Y. and W/Tensae, M. and G/Selassie, S. and Haile, T. and Bane, A. and Ali, A. and Mesfin, G. and Seboxa, T (2012) 'Veno-occlusive liver disease: a case report', Ethiopian Medical Journal, 50 Suppl 2, pp. 47-51. Available at: https://pubmed.ncbi.nlm.nih.gov/22946295/ Clinical study
https://pubmed.ncbi.nlm.nih.gov/22946295/
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.